1. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
2. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. last updated on 21 April 2020, https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
3. Шляхто Е.В. Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801.
4. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505- 53. doi:10.1152/physrev.00023.2016.
5. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation. 2005;111(20):2605-10. doi:10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
6. Sommerstein R, Gräni C. Rapid response: re: preventing a covid‐19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid‐19. BMJ 2020; 368. doi:10.1136/bmj.m810.
7. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID19 pandemic? J Hypertens. 2020;38(5):781-2. doi:10.1097/HJH.0000000000002450.
8. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi:10.1002/path.1570.
9. Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoVInduced Acute Lung Injury. Virol Sin. 2020. doi:10.1007/s12250-020-00205-6. Online ahead of print.
10. Guang Ya, Zihu T, Ling Z, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. doi:10.1101/2020.03.31.20038935.
11. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. NEJM. 2020;382(17):1653-9. doi:10.1056/NEJMsr2005760.
12. Sommerstein R, Kochen MM, Messerli FH, Gräni Ch. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.016509.
13. Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x.
14. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054- 62. doi:10.1016/S0140-6736(20)30566-3.
15. Juyi Li, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1624.
16. Zoler ML. ACEI/ARBs Linked With Survival in Hypertensive, Chinese COVID-19 Patients Medscape. Medical News April 22. 2020.
17. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. doi:10.1002/ddr.21656. Online ahead of print.
